First line therapy for detrusor overactivity in patients with neurogenic bladder consists of oral agents, most commonly antimuscarinics. However, many patients suffer from severe side effects such as dry mouth, constipation and heat intolerance and therefore cannot tolerate the systemic administration of these agents. Intravesical administration, which is simply introducing the drug directly into the bladder through a catheter, attempts to maximize the local action of the medication while limiting the systemic absorption and thereby decreasing the emergence and/or severity of side effects.
- 3.Schroder A, Albrecht U, Schnitker J, Reitz A, Stein R. Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: a randomized, prospective, controlled multi-center trial. Neurourol Urodyn. 2016;35:582–8.CrossRefGoogle Scholar